Hovione, a global contract development and manufacturing organization (CDMO), announced the completion of its initial $100 million investment cycle to expand its New Jersey manufacturing site, marking a significant step in the company’s long-term strategy to scale U.S. operations and advance integrated drug substance and product manufacturing capabilities.
The expansion includes a new 31,000-square-foot facility housing two size-3 spray dryers (PSD-3) designed for large-scale production of amorphous solid dispersions (ASDs). This critical solubility-enhancement technology can benefit approximately 70% of drugs in development. This investment more than doubles Hovione’s spray drying capacity in the U.S., reinforcing the company’s leadership in improving drug solubility and bioavailability through advanced formulation technologies.
Construction at the East Windsor site is already underway, with GMP operations expected to begin in Q2 2026. The expanded site will form part of Hovione’s global manufacturing network, which also includes facilities in Portugal, Ireland, and China, creating an integrated ecosystem to support the full drug development lifecycle from early-stage formulation through to commercialization.
In addition to its current expansion, Hovione has also acquired an adjacent 125,000-square-foot greenfield site to accommodate future growth. The new space will enable the company to introduce continuous and batch tableting capabilities, expand R&D and quality control functions, and integrate next-generation digital and automation technologies to enhance operational excellence further.
Hovione’s investment in New Jersey reflects its commitment to supporting pharmaceutical and biotech partners that require U.S.-based capacity for complex, high-value drug products while minimizing the risks associated with multi-site tech transfer. By co-locating development, scale-up, and manufacturing, Hovione aims to accelerate customers’ timelines from drug substance to final dosage form within a unified quality framework.
KEY QUOTES
“Since launching our New Jersey operations in 2002, Hovione has been one of the longest established European CDMOs in the United States. This investment reinforces Hovione’s leadership in spray drying – a core technology platform where we have built extensive know-how and capabilities. By continuing to advance our platforms and expand capacity in the U.S., we are strengthening the foundation that enables our partners to bring complex medicines to patients more efficiently.”
Jean-Luc Herbeaux, Ph.D., CEO, Hovione
“This investment addresses growing customer demand for U.S.-based capacity and integrated solutions that shorten development timelines and reduce tech transfer complexity. By consolidating development, scale-up, and commercial manufacturing within a single quality and governance framework, we provide customers with seamless execution from drug substance to drug product.”
Jean-Luc Herbeaux, Ph.D., CEO, Hovione
“This expansion in New Jersey marks a significant step in extending our capabilities in the U.S., which go far beyond machine time or equipment capacity. We are integrating our teams, specialized assets, proprietary technologies, and digital systems to deliver distinctive end-to-end ASD and continuous tableting platforms to our customers. Through our new strategic engagement model, customers can gain privileged access to innovation and assets that accelerate their programs and create long-term value.”
David Basile, Vice President of Technical Operations – Americas, Hovione
